obesity

News

Novo Nordisk buys another obesity biotech

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 milli

News

Semaglutide scores again, this time in heart failure

The list of benefits for Novo Nordisk's semaglutide keeps getting longer.

News

Boehringer preps phase 3 for dual-action obesity drug

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.

News

Four digital weight-loss programmes get NICE support

People seeking help from the NHS to lose weight may soon be eligible to use digital programmes delivered via a smartphone or computer.

News

Novo Nordisk buys Inversago for $1bn as Wegovy sales soar

Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.

News

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

Novo Nordisk buys another obesity biotech

Semaglutide scores again, this time in heart failure

Boehringer preps phase 3 for dual-action obesity drug

Four digital weight-loss programmes get NICE support

Novo Nordisk buys Inversago for $1bn as Wegovy sales soar

Advantage Novo Nordisk in battle of weight-loss drugs

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks